Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept, PTCy, and Bortezomib for GVHD Prevention
NCT06681922Phase 2Recruiting
- Sponsor
- Northwell Health
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in graft-versus-host disease (GVHD), sponsored by Northwell Health. Primary endpoint: Maximum Tolerated Dose up to 2 years. Started Sep 2024; status: recruiting.
02
Drugs
abatacept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06681922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681922.